Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
TipRanks (Mon, 22-Apr 4:42 PM ET)
Business Wire (Mon, 22-Apr 4:30 PM ET)
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Business Wire (Mon, 8-Apr 7:00 AM ET)
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 28-Mar 5:19 PM ET)
Business Wire (Tue, 19-Mar 4:10 PM ET)
Business Wire (Mon, 11-Mar 7:00 AM ET)
Business Wire (Mon, 5-Feb 4:01 PM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of April 26, 2024, ACET stock price declined to $1.68 with 1,239,622 million shares trading.
ACET has a beta of 1.05, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.01 to the broad based SPY ETF.
ACET has a market cap of $138.02 million. This is considered a Micro Cap stock.
Last quarter Adicet Bio reported $0 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-620,000 and met earnings estimates .
In the last 3 years, ACET stock traded as high as $21.87 and as low as $1.10.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, IWM, IWN, VTWO.
ACET has underperformed the market in the last year with a price return of -72.4% while the SPY ETF gained +26.8%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.0% and -25.0%, respectively, while the SPY returned +4.5% and -1.9%, respectively.
ACET support price is $1.72 and resistance is $1.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET stock will trade within this expected range on the day.